Leading with
Experience
About Us
CERECIN IS A HEALTHCARE COMPANY WITH MORE THAN 20 YEARS OF INNOVATION AND LEADERSHIP IN BRAIN HEALTH
About Us
We develop novel evidence-based therapeutics and products that aim to help millions of people. These solutions are designed to target conditions ranging from memory impairment to Alzheimer’s disease and other devastating neurological diseases.
Mission
Live in a world in which people are not burdened by neurological disease
Vision
Create impact through the development of medicines that treat, cure and prevent diseases of the brain
History
Cerecin pioneers the science of neuro-metabolism and ketogenic drug development. With a world-class team and strong strategic partners, Nestle and Wilmar, Cerecin has bold ambitions to develop a portfolio of first-in-class products that help millions of patients throughout the world.
Management
Board Of Directors
Dr. Stacey는 의료계에 15년이 넘는 경력을 가지고 있으며; 의료인, 중역, 기업가 및 투자자로 종사하였습니다. 세레신에 합류하기 전에 그는 Nestlé가 후원하는 운영 규모 15억 달러의 벤처 캐피탈과 사모 펀드 그룹인 Inventages에서 근무하였습니다. 여기서 그는 CNS 지분과 아시아의 펀드 지분을 관리하였습니다. Inventages에 근무하기 전에 Dr. Stacey는 King’s College London에서 의학 학위를 받은 후 정형외과용 의료기기 회사를 운영하였으며, 다수의 초기 단계 의료 회사에서 근무하였고, 외상 및 재건 외과 의사로 종사하였습니다. 그는 University of College London에서 학부 학위를 마쳤으며, 신경 과학을 전공하고 연구하였습니다. Dr. Stacey는 또한 London Business School과 Wharton School에서 MBA를 받았습니다.
Dr. Henderson는 신경퇴행성 질병의 연구에 15년 이상의 경력을 가지고 있습니다. 이전에는 콜로라도 대학교에서 노화 유전학을 연구하였으며, GenoPlex, Inc.에서 노화 방지 기술을 연구하는 선임 과학자였습니다. Dr. Henderson은 시카고대학교에서 분자 유전학과 세포 생물학의 박사 학위를 받았으며, 워싱턴대학교에서 생물학 학사를 받았습니다.
Daniel has more than 20 years of experience in global capital markets dealing with equity initial public offering, RCPS, CPS, 144A/REGS bond issuance, convertible bond and syndicated loans. His career has spanned Korea and Hong Kong where he was responsible for global capital markets origination at Deutsche Bank covering major Korean conglomerates and quasi-sovereign entities. He continued his capital markets career at Fitch Ratings, heading issuer business management and investor development. Prior to joining Cerecin, Daniel was a member of the executive board and CFO for ONCOCROSS, a Korea-based AI Biotech company, and successfully led its KOSDAQ IPO, managing the entire process including technical assessment, drafting of ERA/SRS, KRX and FSS review meetings, and investor roadshows in Seoul, Hong Kong, and Singapore. Daniel earned his B.A.(Hon) Economics at Queen’s University in Ontario, Canada, his M.A. International Studies at Yonsei University, and obtained a certificate of AI in Healthcare from MIT Sloan Executive Education.
John Yoon is Managing Director, Asia Pacific at Joint Commission International, where he leads regional strategy and works with health ministries and leading healthcare providers to advance care quality and system performance across Asia. With over 15 years of international healthcare leadership, he has held senior roles at Philips Healthcare, overseeing the Philips Solutions Business and Philips Capital divisions. Previously, he held executive positions at Mubadala Health, an integrated healthcare network backed by Abu Dhabi’s sovereign wealth fund, and led global strategy at Wooridul Spine Hospital, Asia’s largest spine care provider, where he drove international partnerships and hospital expansion. Mr. Yoon began his career in corporate finance at Hana Bank, before moving into roles at various boutique venture capital and advisory firms, gaining broad exposure to early-stage investments and strategic consulting. John holds an MBA from IMD Business School in Switzerland and a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health in Baltimore, United States.
Mr. Kim은 IPO 서비스를 전문으로 하는 해외 금융 서비스를 제공하는 K&T Partners의 CEO 및 설립자입니다. 세레신의 이사회에 참여하기 전에 Mr. Kim은 거의 20년 동안 IPO 자문 서비스의 투자자이면서 리더였습니다. 그의 기업인 K&T Partners는 아시아 시장에서 상장하려고 하는 회사에게 자문을 제공하고, 해외 생명 공학 회사들에게 자금 조달 및 IPO 관련 서비스를 제공하였습니다. 2011년 K&T partners를 설립하기 전에 Mr. Kim은 한국 시티은행과 우리 금융 증권에서 다양한 역할을 맡고 있었습니다. 업계에서 쌓은 경험과 지식을 토대로 그는 국세청 조사국과 부동산과세국에서 초빙 강사로 근무하였습니다. 그는 또한 금융에 대하여 5권의 저서를 출판한 저자이기도 합니다.
Marie Ha is Vice President and General Manager at Becton, Dickinson and company based in NJ, where she responsible for leading and overseeing over $800 million surgical solution portfolio with a focus on global strategy execution and innovation. Prior to joining Becton Dickenson in 2014, Marie held several commercial leadership roles with Johnson & Johnson based in NJ since 2003. She has over 20 years of experience across pharmaceutical, medical device, and biologic businesses; general management, marketing, sales management, market access, and consulting. Marie holds an MBA from The Wharton School – University of Pennsylvania, an MS in Medicinal Chemistry from Seoul National University, and registered pharmacist in Korea.
Rahul Rajashekar Shastry has held various leadership and management roles over his 13 years at Wilmar in portfolio management, trading, business development and supply chain operations. His expertise spans Biofuels & Oleochemicals, Sustainability & Supply Chain management of various agricultural commodities, and Corporate Venturing focused on deploying investment strategies aimed at driving innovation and sustainable growth in Agriculture, Energy and Bio-Solutions. He was an integral part of Wilmar’s Corporate Venture Capital arm that invested into Cerecin in 2018 and has been on the Board since then. Rahul holds a MBA from Singapore Management University, a MSc (Advanced Mechanical Engineering) from Cranfield University, and B.E in Mechanical Engineering.
Ralf Loehrl is the Head of Ventures, Licensing, and Integration at the Nestle Group, where he oversees the Group’s direct investments, strategic partnerships, and fund management activities. With over 13 years of experience at Nestle, Mr. Loehrl began his career in the Nutrition and Health division before transitioning to the corporate group. Before joining Nestle, he worked in strategy consulting, focusing on corporate strategy, business development, M&A, and ventures, as well as logistics at BASF. A Swiss national, Mr. Loehrl is based out of Nestle’s global headquarters in Vevey, Switzerland.
Mr. Reichenberger는 2005년 lnventages에 무한책임 사원으로 합류하였습니다. Lnventages에서 그는 예방, 영양, 약학 및 건강 분야의 혁신적 창업 회사와 매수 회사에 투자한다. 이전에 그는 세계 최대의 식음료 회사인 Nestle의 최고 재무 책임자였으며, 거기서 그는 30년의 성공적인 경력을 쌓았습니다. 그는 서로 다른 나라에서 국제 경영 직책을 거치며 성장하여 마침내 글로벌 최고 재무 책임자에 이르러 5년 (2001-2005) 동안 근무하게 되었습니다.
Alzheimer's Disease Scientific Advisory Board
Dr. Christopher Chen은 케임브리지 대학교의 Fitzwilliam College에서 임상전 의학을 연구하였으며, 거기서 생리학과 심리학을 전공하였습니다. 그는 임상 수련을 옥스포드 대학교에서 하였으며, 거기서 그는 런던의 신경학 연구소와 공동으로 연구원을 맡고 있었습니다. 그는 현재 싱가폴 국립대학교의 약리학과 부교수를 맡고 있으며, , National University Health System의 기억 노화 및 인지 센터의 소장을 맡고 있습니다. 1995년 싱가폴에 돌아간 후로 Dr. Chen은 종합적인 다분야 치매 프로그램을 개발하였으며, 아시아 태평양 지역과 이를 넘어선 협력 연구를 장려하였습니다. 그는 현재 아시아 지역에 만연하고 해당하는 질병에 대한 혁신적인 실험을 위한 지역 네트워크를 구축하는데 집중하고 있습니다. 그는 또한 폭넓은 국제적 협력을 받아 뇌졸중과 치매에 중점을 두는 실험 단위를 구축하였습니다. 그의 주요 연구 및 임상적 관심은 신경 화학, 분자 생물학 및 뇌졸중과 치매 치료입니다. 그는 현재 다수의 연구원들이 개시한 실험, 그리고 뇌혈관 질환과 신경 퇴행으로 인한 인지 장애와 치매의 자연 이력, 위험 요소 및 이를 예방하기 위한 바이오 마커와 치료를 연구하는 예상 집단 연구의 책임 연구원입니다.
MD와 ScD인 Jeffrey L. Cummings는 네바다 주에서 뇌 건강을 위한 Cleveland Clinic Lou Ruvo Center의 신경 퇴행 및 중개 신경 과학 센터의 소장이며, Case Western Reserve University의 Cleveland Clinic Lerner 의대의 교수 (신경학)입니다. 그는 이전에 Cleveland Clinic Lou Ruvo Center for Brain Health의 소장이었으며, 뇌 건강에 대한 Camille and Larry Ruvo 석좌 교수였습니다. Cleveland Clinic에 오기 전에 Dr Cummings는 UCLA에서 신경학과 정신의학의 Augustus Rose 석좌 교수였으며, UCLA의 알츠하이머 병의 연구를 위한 Mary S. Easton Center의 소장과, UCLA의 신경 치료를 위한 Deane F. Johnson Center의 소장을 역임하였습니다. 그는 43권의 책을 저술 또는 편집하였으며, 700편이 넘는 동료가 심사하는 논문을 발표하였습니다. 그는 뇌 질환에 대한 임상 실험과 새로운 치료법의 개발, 그리고 신경 과학과 사회와의 인터페이스에 관심을 가지고 있습니다.
Dr. Farlow는 인디애나 알츠하이머병 센터의 신경학과 교수입니다. 그는 약 30년 동안 알츠하이머병 (AD) 및 기타 치매 증상과 같은 신경퇴행성 질환 환자의 연구와 임상 치료에 종사하였습니다. 그는 조사 약물 실험, 분자 유전학 및 AD에 대한 바이오 마커에 중점을 두고 AD 및 관련된 치매 증상의 임상 및 기초 과학 분야에 논문을 발표하였다. 그는 돌연변이와 관련된 알츠하이머병을 가진 기술된 세계의 2등급 가족에 대한 책임 연구원이었으며, 알츠하이머병에 대한 첫 성공적인 동물 모델 (PD-APP 생쥐)에 대한 공동 보유자입니다. 그는 인디애나 알츠하이머병 센터의 부소장이며 인디애나 ADC의 부 책임자입니다. 그는 여러 데이터 안전 모니터링 위원회와 산업에 대한 자문 위원회의 일원으로 역할을 하며 의장을 맡고 있습니다. 그는 지역적으로, 그리고 전국적으로 많은 강연을 하고 있습니다. 그는 AD의 새로운 치료법과 알츠하이머병 신경 촬영 계획을 연구하는 AD 협력 연구 기관의 인디애나 현장의 책임 연구원입니다. 그는 DISCOVER 연구의 공동 PI이며 알츠하이머병에 대한 새로운 진단 테스트의 다중 센터 개발을 위한 인디애나 현장의 책임 연구원입니다.
Professor Han is an Advisory Professor in the Department of Neurology at Konkuk University Medical Center, with significant contributions to dementia research. He served as an Investigator for the Clarity AD study, a Phase 3 trial of lecanemab in early Alzheimer’s disease, and was involved in a Phase 3 clinical trial evaluating the efficacy and safety of a donepezil transdermal patch, as well as a preliminary study on a rivastigmine patch for Korean dementia patients. He received the Presidential Award in 2009 and the Minister of Health and Welfare Award in 2003 for his exceptional work in the field. Throughout his career, he has held several leadership positions, including President of the Medical Department and Medical Director at Konkuk University.
Shim Yong Soo is a Professor in the Department of Neurology at The Catholic University of Korea Eunpyeong St. Mary’s Hospital in Seoul, Korea. He specializes in dementia, focusing on language and memory impairments, including mild cognitive impairment (MCI), Alzheimer’s disease (AD), and vascular dementia. He has authored numerous theses, many of which concentrate on Alzheimer’s disease. His research encompasses several key areas: early (prodromal to mild) Alzheimer’s disease treatment drug clinical trials, biomarkers and prognostic factors for Alzheimer’s disease, treatment and management of dementia patients through digital therapeutics, and clinical trials for dementia treatment drugs. In recognition of his contributions to the field, he has received several awards from the Korean Dementia Society, including the Young Researcher Award, Outstanding Paper Award and Outstanding Presentation Award. Additionally, he serves as the Director of the Eunpyeong-gu Dementia Care Center and holds the position of Non-Executive Director of the Korean Dementia Association.
Dr. Weiner has been doing research for over 50 years and is the Principal Investigator of the Alzheimer’s Disease Neuroimaging Initiative, aimed at validating biomarkers for Alzheimer’s disease. He also launched BrainHealthRegistry.org, to accelerate development of effective treatments for brain diseases. His overall research goals are to participate in the development of effective treatments and methods for early detection of Alzheimer’s disease and other brain disorders. In 1980, Dr. Weiner was one of the first investigators to use nuclear magnetic resonance to investigate the metabolism of organs inside a living animal. This technique subsequently became magnetic resonance spectroscopy (MRS). In 1988, his group used MRS to show that the amino acid, N-acetylaspartate (NAA), a marker of healthy nerve cells, is reduced in the epileptic focus in the brain. This marker is now used to help identify the epileptic focus prior to surgery in epilepsy patients. In 2004, Dr. Weiner’s group reported that reduced NAA predicts development of Alzheimer’s disease in mildly impaired elderly subjects. They have also demonstrated that brain blood flow is reduced in Alzheimer’s disease and in patients with mild impairment. Dr. Weiner has over 800 published articles. In 2006, Dr. Weiner received the William S. Middleton Award, the highest scientific honor bestowed by the Department of Veterans Affairs. In 2010, he was named one of the “Rock Stars of Science”. He also received the Gold Medal of Paul Sabatier University and the City of Toulouse, France. In 2011, he received the Ronald and Nancy Reagan Research Award from the Alzheimer’s Association. In 2012, he received the Potamkin Award from the American Academy of Neurology and the American Brain Foundation.
Professor Vellas (MD, PhD)는 현재 Toulouse Gerontopole의 의장이며, Toulouse 대학병원의 내과 및 노인병학과의 과장이며, Toulouse 대학교의 알츠하이머병 임상연구센터와 INSERM (국립 의료연구소)의 노화에 대한 1027 단위의 소장입니다. 그는 또한 IAGG (국제 노인학 및 노인병학 협회) 회장을 역임하였습니다. 그는 의학 학위 (MD)와 박사 학위를 Paul Sabatier 대학교와 Academy of Toulouse에서 받았으며, 알츠하이머병과 쇠약 분야의 대형 실험에 관여하였습니다. Professor Vellas는 특히 알츠하이머병과 질병 변경 치료, 쇠약 및 근육감소증 분야에 637편 이상의 논문을 발표하였습니다. Prof. Vellas는 E.A.D.C. (유럽 알츠하이머병 컨소시엄)의 설립자입니다.
Migraine Scientific Advisory Board
MD, FRCP (C), FACP인 Dr David W Dodick는 애리조나 주 Scottsdale에 있는 Mayo Clinic의 Mayo Clinic 의대 신경학 교수이며 신경학의 고문 의사입니다. 그는 Mayo Clinic의 두통 프로그램과 스포츠 신경학 및 뇌진탕 프로그램의 소장을 맡고 있습니다. 그는 캐나다의 Royal College of Physicians and Surgeons가 인증하는 이사회와 미국 정신의학 및 신경학 협회 (ABPN)의 회원입니다. 그는 또한 두통 의학의 United Council for Neurologic Subspecialties 인증과 혈관 신경확의 ABPN 인증을 보유하고 있으며, 350 편의 동료가 심사한 논문을 발표하였으며, 10 권의 책을 집필/편집하였습니다. 그는 스포츠 뇌진탕 학회 실무그룹과 미국 신경학회의 AAN 연례 스포츠 뇌진탕 학회의 의장, 그리고 AAN의 연례 회의 위원회의 위원을 맡고 있습니다. 그는 Lancet Neurology, Journal of Neurology, Neurosurgery and Psychiatry, Postgraduate Medicine, Headache, and Cephalalgia와 같은 저널의 편집위원회의 위원을 맡고 있으며, 미국 두통 학회의 회장을 역임하였으며, 미국 편두통 재단의 의장과 미국 학술 두통 컨소시엄의 소장을 맡고 있으며, Cephalalgia의 편집장을 역임한 적이 있습니다.
Professor Goadsby is the NIHR Clinical Research Network National Specialty Lead for Neurological Disorders, training at the University of New South Wales and with Prof James W. Lance and clinical neurophysiology with Prof David Burke in Sydney. After post-doctoral work in New York with Don Reis at Cornell, with Jacques Seylaz at Universite VII, Paris, and post-graduate neurology training at Queen Square, London with Professors C David Marsden, Andrew Lees, Anita Harding and W Ian McDonald, he returned to the University of New South Wales, and the Prince of Wales Hospital, Sydney as a consultant neurologist , was Professor of Clinical Neurology and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London until 2007. He has been Professor of Neurology, Department of Neurology, University of California, San Francisco since 2007. He has been an Honorary Consultant Neurologist at the Hospital for Sick Children, Great Ormond St, London since 1998. In 2013 he was appointed Director, NIHR-Wellcome Trust King’s Clinical Research Facility, King’s College Hospital, Professor of Neurology at King’s College London and Honorary Consultant Neurologist, King’s College Hospital. His major research interests are in the basic mechanisms of primary headache disorders, such as migraine and cluster headache, in both experimental and clinical settings, and translating these insights into their better management.
Epilepsy Scientific Advisory Board
Dr. Andrew Lux는 Bristol’s Royal Hospital for Children의 고문 소아 신경과 의사이며, 거기서 소아 신경학의 모든 분야에서 입원 환자와 외래 환자에 대한 임무를 수행합니다. 그는 또한 Plymouth에 있는 Derriford Hospital에서 방문 전문의 클리닉을 수행합니다. 그는 간질, 신생아 시기 및 유아기의 발작, 태아의 신경계의 이상, 그리고 신경안과학에 대하여 그의 과 내에서 특별한 책임을 맡고 있으며; 그리고 그는 부신백질형 성장애 (ALD)에 대한 전문의 다부문 클리닉의 책임자이며, 브리스톨 대학교에서 소아 건강에 대한 명예 선임 임상 강사입니다.
Dr. Eric Kossoff, MD는 유아기 발작과 간질의 진단과 치료, 특히 식사, 신경 자극 및 수술과 같은 약물 치료 이외의 치료에 중점을 두고 있습니다. 그는 간질에 대한 식이요법 치료 (케톤 식이요법)에 대한 세계적 전문가이며, 이 치료법에 대해 전세계에서 강연을 합니다. 그의 구체적인 관심 분야로는 케톤 식이요법, 어린이와 어른들 위한 수정된 애트킨스 식이요법, 영아 연축, 양성 롤란드 간질, 편두통과 간질의 상호 작용, 그리고 Sturge-Weber 증후군 등이 있습니다. 그는 소아 신경학 수련의 프로그램의 책임자이며, 존스 홉킨스 대학교 의대의 신경학과 소아과 교수이며, 소아 신경 질환 치료와 케톤 식이요법 제6판의 공동 저자입니다.
Professor Helen Cross is The Prince of Wales’s Chair of Childhood Epilepsy and Head of the Developmental Neuroscience Programme at UCL-Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology Great Ormond Street Hospital for Children NHS Foundation Trust, London and Young Epilepsy, Lingfield, UK. Helen’s research has been targeted at improving outcomes in early onset epilepsy, specifically in assessing the role of surgery and ketogenic diet. Helen has also held key leadership roles both nationally and internationally. Helen is Treasurer of the International League Against Epilepsy 2017-2021 (Secretary General 2013-2017), Clinical Advisor to the National Children’s Epilepsy Surgery Service, and Clinical Advisor to the update of the NICE guidelines for Childhood Epilepsy 2018-2021. She developed, as Coordinator, the European Reference Network for Rare and Complex Epilepsies (EpiCARE) launched in 2017.
A leading Korean expert in pediatric epilepsy treatment, Professor Kim was the first in Korea to introduce the ketogenic diet in treating epilepsy. He is recognized for diagnostic and treatment capabilities through various anti-epileptic therapies and surgery. He is also the Former President of the Korean Epilepsy Society and currently heads the Korean Bureau for Epilepsy.
Professor Scheffer is a Paediatric Neurologist, Clinician-Scientist. She is the Chair of Paediatric Neurology at The University of Melbourne and Senior Principal Research Fellow at the Florey Institute of Neuroscience and Mental Health. Professor Scheffer is also the Immediate Past President of the Australian Academy of Health and Medical Sciences. Her work has resulted in major paradigm shifts in epilepsy classification over many years. And formed the essential basis for successful gene discovery such that her larger collaborative group has been the leaders in epilepsy gene identification for 18 years since they discovered the first gene associated with epilepsy. Her work described a range of novel epilepsy syndromes beginning in infancy, childhood and adult life., including sodium channel disorders such as Dravet syndrome and related epilepsies .. Her recent work on a fascinating disorder occurring exclusively in females, Epilepsy limited to Females with Mental Retardation, is changing the way family histories are interpreted and will benefit affected women and transmitting men by improving genetic counseling. She has considerably expanded our understanding of the spectrum of epilepsies associated with glucose transporter deficiency; this body of work carries major treatment implications as this disorder responds to the ketogenic diet. Her work is important as it has changed our concepts of the underlying neurobiology of genetic epilepsies.
Dr. Jacqueline French is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase clinical trials in epilepsy, and has developed new methodologies for epilepsy trials. Dr. French trained in Neurology at Mount Sinai Hospital in New York and did her fellowship training in EEG and epilepsy at Mount Sinai Hospital and Yale University. Dr. French has focused her research efforts on the development of new therapeutics for epilepsy, and new methodologies for clinical trials. Over the past 20 years she has served as the Principle investigator on a number of trials for new epilepsy drugs. She is responsible for the creation of a number of new trial designs that have been accepted by regulatory authorities for new drug approval. Dr. French has been active in creating guidelines for the American Academy of Neurology and the International League Against Epilepsy. She chaired an AAN/AES committee that produced two widely quoted guidelines on the use of new antiepileptic drugs. She has served as chair of the International League Against Epilepsy North American Regional Commission, and Commission on Therapeutic strategies. Dr. French serves as the Chief Medical/Innovation Officer of the Epilepsy Foundation. She is the past president of the American Epilepsy Society. She is the past Secretary of the American Society of Experimental Neurotherapeutics. She is the recipient of the American Epilepsy Society Lennox Award (2017) and Service Award (2005), the Epilepsy Foundation Hero award (2013), and is an ILAE Ambassador for Epilepsy. She has authored over 300 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and the use of antiepileptic drugs.
Dr. Rho is the division chief of neurology at Rady Children’s Hospital-San Diego and a professor of neurosciences and pediatrics at UC San Diego School of Medicine. His clinical expertise is in general pediatric neurology and pediatric epilepsy, with an emphasis on pharmacological therapies and metabolic approaches toward epilepsy treatment, such as the ketogenic diet. His main research interests for patients, including at Rady Children’s Hospital-San Diego, are the mechanisms underlying the anti-seizure and neuroprotective effects of the ketogenic diet and its clinical variants. Dr. Rho’s research activities involving patient care and treating neurological conditions have been funded by grants from the National Institutes of Health, Canadian Institutes of Health Research, Brain Canada and a variety of intramural and extramural public and private sector sources.Prior to his current position providing patient care as chief of pediatric neurology at Rady Children’s Hospital-San Diego, Dr. Rho held full-time academic faculty appointments at the University of Washington (Seattle) and Seattle Children’s Hospital; the University of California at Irvine; the University of Arizona and Arizona State University (Barrow Neurological Institute in Phoenix); and most recently, the Alberta Children’s Hospital and the University of Calgary (Alberta, Canada).
Dr. Stacey has over 15 years of experience in healthcare; working as a healthcare provider, executive, entrepreneur and investor. Prior to joining Cerecin, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. Here he led the CNS interest as well as the funds interest in Asia. Prior to Inventages, Dr. Stacey ran an orthopedic medical device company and worked for a number of early stage healthcare companies.
Charles serves on the Board of Governors for the Accreditation Council for Medical Affairs. Dr. Stacey received his medical degree from King's College London and practiced as a trauma and reconstructive surgeon. His undergraduate degree and research were in the neurosciences at University of College London. Dr. Stacey also completed an MBA at the London Business School and the Wharton School.
Korean 
English